Dr Kuno van der Post
OmniComm Systems, Inc.
FORT LAUDERDALE, Fla., June 17, 2013 -- OmniComm Systems, Inc. (OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, and Soltex Consulting, LLP, a leading eClinical lifecycle consulting firm, announced their new strategic partnership today. The partnership will allow OmniComm to offer best-in-class process reengineering and change management consulting to its EDC software customers, and augment OmniComm's own study build services, while allowing Soltex to offer its clients access to one of the most intuitive, productive EDC suites available on the market today.
"We look forward to a successful partnership with Soltex," said Stephen Johnson, President and COO of OmniComm Systems. "Their reputation and expertise in this industry make them the ideal company to collaborate with as we strive to deliver efficiencies throughout the clinical trial process."
"We are excited to partner with OmniComm – they are truly on the forefront of technology innovation," said Christie Mahoney, Managing Director of Soltex Consulting, LLP. "TrialMaster and TrialBuilder have much to offer in terms of speed, flexibility, and ease of use, and OmniComm has proven itself able to endure and grow in a competitive and changing marketplace. Our complementary offerings will allow us to deliver maximum value to our clients."
Under the terms of the agreement, OmniComm will be able to access Soltex Consulting's professional services capabilities to help customers drive further efficiencies in their clinical process. Soltex will become a reseller of OmniComm TrialMaster Suite and TrialOne Suite, giving clients access to a robust EDC platform, and will become a study build services provider for OmniComm products.
About OmniComm Systems
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
About Soltex Consulting
Soltex Consulting, LLP (www.SoltexConsulting.com) is an eClinical lifecycle consulting firm that equips study teams at pharmaceutical companies, biotechs, and clinical research organizations with the knowledge to lead life-saving clinical trials. Soltex integrates people, process, and technology to drive efficiencies throughout the clinical trial lifecycle. The firm's service offerings include Change Management Consulting, Process Reengineering, Technology Consulting and EDC Study Build Services. Soltex is headquartered in Princeton, NJ.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.